Internal Medicine, Endocrinology, Diabetes, & Metabolism · Trumbull, CT
NPI
1124209101
Since 2007
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
112 Quarry Rd Ste 250
Trumbull, CT, 06611
Phone (203) 371-7048
Groups this clinician bills Medicare through
Medicare paid, 2024
$163K
8,456 services
Medicare patients, 2024
338
Average age 73
Drug cost, 2024
$3.0M
5,324 prescriptions
Company payments, 2025
$424
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Maryanne Horta was code J0897 (injection, denosumab, 1 mg), 3,000 times for 33 patients. In total Maryanne Horta billed 8,456 services in 20 codes, and Medicare paid $163K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-03-29.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 3,000 | 33 | $20.58 | $62K |
| 99214 Office E&M - Established | Office | 364 | 193 | $99.55 | $36K |
| 82962 Clinical Chemistry | Office | 233 | 118 | $3.21 | $748 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 163 | 139 | $13.94 | $2,272 |
| 83036 Blood Count | Office | 146 | 90 | $9.52 | $1,390 |
| J3489 Injection, zoledronic acid, 1 mg | Office | 125 | 25 | $4.97 | $622 |
| 99213 Office E&M - Established | Office | 108 | 93 | $66.06 | $7,135 |
| 95251 Test - Miscellaneous | Office | 84 | 38 | $28.65 | $2,407 |
| 96372 Injection Administration | Office | 71 | 39 | $11.93 | $847 |
| 99204 Office E&M - New | Office | 52 | 52 | $133.89 | $6,963 |
| 99203 Office E&M - New | Office | 32 | 32 | $81.27 | $2,601 |
| 76536 Ultrasound - Nonspecific | Office | 32 | 30 | $85.56 | $2,738 |
| 96365 Intravenous Infusion, Hydration | Office | 26 | 26 | $51.93 | $1,350 |
By year: 2022 $96K for 3,435 services; 2023 $126K for 5,735 services; 2024 $163K for 8,456 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 82962 Clinical Chemistry | 233 | 118 | $3.21 | $748 |
| 83036 Blood Count | 146 | 90 | $9.52 | $1,390 |
Medicare prescription drug claims, 2024
In 2024, the drug Maryanne Horta prescribed most often to Medicare patients was Levothyroxine Sodium, with 486 prescriptions and refills. In total Maryanne Horta wrote 5,324 Medicare prescriptions that cost $3.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 486 | 1,248 | 139 | $5,102 |
| Mounjaro Tirzepatide | 479 | 741 | 104 | $820K |
| Ozempic Semaglutide | 334 | 617 | 89 | $610K |
| Metformin Hcl Er Metformin Hcl | 276 | 723 | 96 | $3,513 |
| Jardiance Empagliflozin | 240 | 503 | 72 | $300K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 223 | 565 | 79 | $25K |
| Alendronate Sodium Generic | 217 | 568 | 75 | $1,903 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 176 | 464 | 78 | $21K |
| Metformin Hcl Generic | 144 | 422 | 52 | $1,054 |
| Methimazole Generic | 122 | 312 | 34 | $826 |
| Tresiba Flextouch U-100 Insulin Degludec | 119 | 335 | 48 | $67K |
| Insulin Lispro Kwikpen U-100 Insulin Lispro | 117 | 232 | 39 | $23K |
| Glimepiride Generic | 102 | 268 | 35 | $726 |
| Tresiba Flextouch U-200 Insulin Degludec | 95 | 213 | 33 | $94K |
| Atorvastatin Calcium Generic | 91 | 271 | 37 | $545 |
Brand drugs: 2,767 claims; generic drugs: 2,122 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Maryanne Horta $424 ($424 in general payments such as food, travel and fees) from 2 companies. The largest payer was Abbott Laboratories with $395.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.